Company Updates - On December 29, 2025, the company announced a long-term strategic partnership with Lanacheng to advance the development of Radionuclide drug conjugates (RDCs) [1] - The collaboration aims to leverage the proprietary Harbour Mice platform to produce fully human monoclonal antibodies in H2L2 and HCAb formats, which are expected to enhance the efficacy of RDCs while reducing side effects [1] Collaborations and Agreements - The company has established multiple overseas licensing agreements, including a long-term global strategic cooperation with BMS on December 17, 2025, which includes an upfront payment of $90 million and potential milestone payments up to $1.035 billion [1] - On November 19, 2025, the company's subsidiary, Nona Bio, signed a non-exclusive licensing agreement with Pfizer for preclinical antibody discovery, granting Pfizer global rights to the HCAb platform, with upfront and milestone payments based on regulatory and clinical achievements [1] - On November 24, 2025, the company announced an expanded collaboration with AstraZeneca, extending the partnership to include ADC and TCE drugs [2] Financial Forecast and Valuation - Due to increased revenue from business development upfront payments, the company raised its 2026 profit forecast by 228% to $6.2 million and introduced a new profit forecast of $6.0 million for 2027 [2] - The target price has been adjusted upward by 34.3% to HKD 18.00, indicating a potential upside of 44.5% from the current stock price [2]
和铂医药-B(02142.HK)：平台合作持续兑现 助力全球新药研发